



**Supplementary Figure 5: Combination of MEK inhibitor with venetoclax in primary patient samples and KOPN-8 cells.** A) Five patient samples were tested with trametinib, venetoclax or the combination of venetoclax with trametinib. Shown is the AUC for the individual compounds and the combination. Red dot indicates a sample with a Ras pathway mutation. Shown is the mean +/- SD. KOPN-8 cells were treated with the indicated range of concentrations of trametinib (B) and selumetinib (C) for two days. Western immunoblotting showing decrease in pERK and a concentration-dependent increase in BIM. D) KOPN-8 cells were treated with a combination of trametinib with venetoclax at the indicated concentrations for 3 days. Western immunoblotting showing increase in NOXA and cleaved BAX for the combination treatment, with an associated increase in BIM in cells treated with trametinib alone or in combination with venetoclax.